Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection

Adam Carrico, Emily M. Cherenack, Margaret E. Roach, Elise D. Riley, Olorunleke Oni, Samantha E. DIlworth, Steven Shoptaw, Peter Hunt, Sabita Roy, Suresh Pallikkuth, Savita G Pahwa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes. Design: Cross-sectional study at baseline for a randomized controlled trial. Methods: HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 + T-cell count, interleukin-6, and alcohol use severity. Results: The sample of 84 virally suppressed MSM had a median CD4 + T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05). Conclusions: Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.

Original languageEnglish (US)
Pages (from-to)767-771
Number of pages5
JournalAIDS
Volume32
Issue number6
DOIs
StatePublished - Mar 27 2018

Fingerprint

Methamphetamine
HIV Infections
Monocytes
HIV
CD4 Lymphocyte Count
Linear Models
T-Lymphocytes
Fatty Acid-Binding Proteins
Viral Load
Cocaine
Toxicology
Interleukin-6
Randomized Controlled Trials
Cross-Sectional Studies
Biomarkers
Alcohols
Urine
Mortality
Therapeutics

Keywords

  • alcohol
  • cocaine
  • HIV
  • immune activation
  • methamphetamine
  • microbial translocation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. / Carrico, Adam; Cherenack, Emily M.; Roach, Margaret E.; Riley, Elise D.; Oni, Olorunleke; DIlworth, Samantha E.; Shoptaw, Steven; Hunt, Peter; Roy, Sabita; Pallikkuth, Suresh; Pahwa, Savita G.

In: AIDS, Vol. 32, No. 6, 27.03.2018, p. 767-771.

Research output: Contribution to journalArticle

Carrico, Adam ; Cherenack, Emily M. ; Roach, Margaret E. ; Riley, Elise D. ; Oni, Olorunleke ; DIlworth, Samantha E. ; Shoptaw, Steven ; Hunt, Peter ; Roy, Sabita ; Pallikkuth, Suresh ; Pahwa, Savita G. / Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. In: AIDS. 2018 ; Vol. 32, No. 6. pp. 767-771.
@article{61d6cec7182547e9b5867d1ccf074930,
title = "Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection",
abstract = "Objective: Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes. Design: Cross-sectional study at baseline for a randomized controlled trial. Methods: HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 + T-cell count, interleukin-6, and alcohol use severity. Results: The sample of 84 virally suppressed MSM had a median CD4 + T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05). Conclusions: Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.",
keywords = "alcohol, cocaine, HIV, immune activation, methamphetamine, microbial translocation",
author = "Adam Carrico and Cherenack, {Emily M.} and Roach, {Margaret E.} and Riley, {Elise D.} and Olorunleke Oni and DIlworth, {Samantha E.} and Steven Shoptaw and Peter Hunt and Sabita Roy and Suresh Pallikkuth and Pahwa, {Savita G}",
year = "2018",
month = "3",
day = "27",
doi = "10.1097/QAD.0000000000001751",
language = "English (US)",
volume = "32",
pages = "767--771",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection

AU - Carrico, Adam

AU - Cherenack, Emily M.

AU - Roach, Margaret E.

AU - Riley, Elise D.

AU - Oni, Olorunleke

AU - DIlworth, Samantha E.

AU - Shoptaw, Steven

AU - Hunt, Peter

AU - Roy, Sabita

AU - Pallikkuth, Suresh

AU - Pahwa, Savita G

PY - 2018/3/27

Y1 - 2018/3/27

N2 - Objective: Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes. Design: Cross-sectional study at baseline for a randomized controlled trial. Methods: HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 + T-cell count, interleukin-6, and alcohol use severity. Results: The sample of 84 virally suppressed MSM had a median CD4 + T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05). Conclusions: Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.

AB - Objective: Microbial translocation and monocyte activation predict mortality in treated HIV. We examined whether substance use independently contributes to these pathophysiologic processes. Design: Cross-sectional study at baseline for a randomized controlled trial. Methods: HIV-positive, methamphetamine-using MSM with undetectable HIV viral load (less than 40 copies/ml) were enrolled. We examined if plasma biomarkers of monocyte activation and intestinal barrier integrity were associated with the following: reactive urine toxicology results (Tox+) for stimulants (i.e., methamphetamine or cocaine) and substance use severity measured by the Addiction Severity Index. Multiple linear regression models adjusted for age, antiretroviral therapy regimen, CD4 + T-cell count, interleukin-6, and alcohol use severity. Results: The sample of 84 virally suppressed MSM had a median CD4 + T-cell count of 645 cells/μl. Those who were Tox+ for stimulants displayed higher soluble CD14 (sCD14) levels (2087 versus 1801 ng/ml; P = 0.009), and this difference remained significant after adjusting for covariates (standardized beta = 0.23, P = 0.026). Greater substance use severity was also independently associated with higher sCD14 after adjusting for covariates (standardized beta = 0.29, P = 0.013). Being Tox+ for stimulants and substance use severity were not associated with soluble CD163 (sCD163) or intestinal fatty acid binding protein (iFABP) levels (P > 0.05). Conclusions: Monocyte activation is one plausible mechanism by which stimulant use may increase clinical HIV progression.

KW - alcohol

KW - cocaine

KW - HIV

KW - immune activation

KW - methamphetamine

KW - microbial translocation

UR - http://www.scopus.com/inward/record.url?scp=85044242121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044242121&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001751

DO - 10.1097/QAD.0000000000001751

M3 - Article

C2 - 29369159

AN - SCOPUS:85044242121

VL - 32

SP - 767

EP - 771

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 6

ER -